Why the study?
Vasopressors and inotropes are widely used to stabilize circulation in patients with acute myocardial infarction complicated by cardiogenic shock, but their effect on survival remains uncertain.
Meta-Analysis (n=2,478)
Answers are grounded in this paper and cite their sources.
No vasopressor or inotrope selection can be guided by mortality benefit in AMI shock; confirms inconsistent effects and leaves open levosimendan RCTs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Vischer et al. (2023) conducted a meta-analysis in AMI-related cardiogenic shock (n=2,478). Levosimendan vs. Control (unexposed to levosimendan) was evaluated on Short-term mortality (<90 days) (RR 0.69, 95% CI 0.47-1.00).
Synapse has enriched 10 related papers. Consider them for comparative context: